KRAS and cancer: This non-genetic mechanism, unprecedented for MTA resistance31 and different from previously reported ones that contribute to adaptive resistance to MEK inhibitors10–12,17–20, is clinically relevant in that it underpinned KRAS-independent survival of KRAS-mutant cancer cells and was activated in patients’ tumors that had acquired resistance to MEK inhibitors.